 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | Janssen Research & Development, LLC |
| Street 1: | Turnhoutseweg 30 |
| Street 2: | |
| City: | Beerse |
| Province: | |
| Post Code: | 2340 |
| Country: | Belgium |
| Phone: | +1-732-524-0400 |
| Email: | janssenrnd@its.jnj.com |
| Web Site: | http://www.janssenrnd.com/ |
|
|
||||||||||||||||||||||||||||
General Information | |
| Organization Type - Primary: | Private Sector |
| Organization Type - Secondary: | Company |
| Is your organization legally registered in your country: | Yes |
| Organization Reach: | International |
| Organization Description: | |
| 1. At Janssen Research & Development, LLC, we are united and energized by one mission – to discover and develop innovative medicines that ease patients' suffering, and solve the most important unmet medical needs of our time. As one of the Janssen Pharmaceutical Companies, our strategy is to identify the biggest unmet medical needs and match them with the best science, internal or external, to find solutions for patients worldwide. We leverage our world-class discovery and development expertise, and operational excellence, to bring innovative, effective treatments in five therapeutic areas: • cardiovascular and metabolism, • immunology, • infectious diseases and vaccines, • neuroscience, and • oncology. 2. The Infectious Diseases and Vaccines (IDV) TA is dedicated to advancing the treatment of contributing to positive change in HIV/AIDS, hepatitis C, tuberculosis, and other infectious diseases. Despite advances in treatment, these diseases continue to claim and limit lives around the world. 3. Under a landmark collaboration signed in June 2009, the TB Alliance and the Company have continued to share their expertise and resources in the development of TMC207 for the treatment of TB. The agreement grants the TB Alliance a royalty-free license for the worldwide development and access to TMC207 in the field of drug-susceptible TB. Tibotec/Janssen will continue to develop TMC207 for the treatment of MDR-TB, and on approval, will establish an access program to ensure the compound reaches those in developing countries which are in need. In addition, the two parties will collaborate on a discovery research program to identify new compounds for the treatment of TB. TMC207 has been studied in Phase II clinical trials in people with MDR-TB evaluating the safety, tolerability and effectiveness of TMC207 in combination with an individualized background regimen (BR) of antibacterial drugs as treatment for MDR-TB. We also have a commitment and regulatory obligation (PIP) to develop a unique formulation of TMC207 |
|
| Total number of staff in your organization: | 100 + |
| Number of full-time staff who are directly involved with TB: | 26 - 50 |
| Number of part-time staff who are directly involved with TB: | 51 - 99 |
| Number of volunteers who are directly involved with TB: | 0 |
| What is your organization's annual budget (USD) dedicated to TB? | Unable to disclose amount |
| How did you hear about the Stop TB Partnership: | Attendance at a TB related event |
| Why do you wish join the Stop TB Partnership: | Technical assistance and advice |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | No |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| We hope to get involved in the future. | |
Geographical Reach | |
| Which country is your headquarters located in: | Belgium |
| Which WHO region is the main focus of your work: | Global |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
Belgium Brazil China Estonia France India Kenya Latvia Mexico Peru Philippines Republic of Korea Russian Federation South Africa Thailand Turkey Ukraine United Kingdom of Great Britain and Northern Ireland United States of America Viet Nam |
Specializations | |
|
Provision of TB products Research and Development |
Specializations in Countries | |
| Research and Development | Belgium |
| Research and Development | Brazil |
| Research and Development | China |
| Research and Development | Estonia |
| Research and Development | France |
| Research and Development | India |
| Research and Development | Kenya |
| Research and Development | Latvia |
| Research and Development | Mexico |
| Research and Development | Peru |
| Research and Development | Philippines |
| Research and Development | Republic of Korea |
| Research and Development | Russian Federation |
| Research and Development | South Africa |
| Research and Development | Thailand |
| Research and Development | Turkey |
| Research and Development | Ukraine |
| Research and Development | United Kingdom of Great Britain and Northern Ireland |
| Research and Development | United States of America |
| Research and Development | Viet Nam |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
Drug-Resistant TB: Tibotec/Janssen will continue to develop TMC207 for the treatment of MDR-TB New TB Drugs: TMC207 has been studied in Phase II clinical trials in people with MDR-TB evaluating the safety, tolerability and effectiveness of TMC207 in combination with an individualized background regimen (BR) of antibacterial drugs as treatment for MDR-TB. We also have a commitment and regulatory obligation (PIP) to develop a unique formulation of TMC207 and conduct clinical studies in a pediatric population. |
|
Declaration | |
| Declaration of interests: No conflicts of interest were delacred. | |
| Application date: | September 7, 2012 |
| Last updated: | September 7, 2012 |